September 9th, 2024 “EURETINA-Brief” Issue No. 299
Dear EURETINA Members, A very warm welcome to the September 9th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue…
EURETINA’s
DIGITAL
NEWSLETTER
Featured Articles
1
September 9th, 2024
Latest News
September 9th, 2024 “EURETINA-Brief” Issue No. 299
Dear EURETINA Members, A very warm welcome to the September 9th, 2024 edition of EURETINA’s…
Variants on the TMEM216 gene suggests an under-reporting from certain ancestry cohorts on non-syndromic retinitis pigmentosa (RP).
Researchers at Moorfields Eye Hospital, the UCL Institute of Ophthalmology, University College London and the…
A systematic review of retinitis pigmentosa and its therapeutic approaches report different treatments and disorders.
Researchers at the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy and the…
Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).
Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio),…